PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1884070
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1884070
Hepatitis A Vaccines Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
Growth Factors of hepatitis A vaccines Market
The global hepatitis A vaccines market is witnessing strong growth due to rising disease prevalence, expanding immunization programs, and increasing government initiatives aimed at preventing hepatitis A infections. According to the report, the market size reached USD 1.24 billion in 2024, is expected to grow to USD 1.26 billion in 2025, and is projected to rise significantly to USD 2.57 billion by 2032, registering a robust CAGR of 10.7% during the forecast period. With a 50% market share in 2024, North America remained the dominant region, reflecting advanced healthcare systems and strong adoption of immunization practices.
Hepatitis A is a viral liver infection transmitted primarily through contaminated food and water or via close personal contact. Symptoms range from fever, nausea, and abdominal discomfort to jaundice and acute liver failure. The infection is particularly prevalent in low- and middle-income regions due to insufficient sanitation, poor hygiene, and restricted access to clean water. As vaccination is the most effective preventive measure, demand for hepatitis A vaccines continues to grow worldwide. Leading companies such as GSK plc, Sanofi, Merck & Co., Inc., and SINOVAC offer globally approved vaccines, contributing to increasing immunization coverage.
Market Drivers
Growing Prevalence of Hepatitis A
Rising hepatitis A cases globally are driving vaccine uptake. Poor sanitation, contaminated water sources, and limited hygiene practices continue to be major risk factors. In Uzbekistan, for example, 9,507 hepatitis A infections among children were reported in the first two months of 2024, highlighting the urgent need for vaccination programs in high-risk regions.
Increased Government Immunization Initiatives
Governments worldwide are expanding national vaccination programs to prevent outbreaks and minimize healthcare expenditures. In the EU/EEA, 4,548 cases were reported in 2022, prompting authorities to reinforce vaccination strategies.
Market Restraints
High Vaccine Costs and Limited Access
Production of hepatitis A vaccines requires cold-chain logistics and stringent regulatory compliance, elevating overall costs. This restricts access in low-income countries. In Mexico, the cost per dose is USD 935.7, and full immunization requires two doses-making the vaccine unaffordable for many. This affordability gap continues to hinder global eradication efforts.
Market Opportunities
Indigenous Vaccine Development in Emerging Markets
Countries such as India and China are investing in domestic vaccine development to reduce reliance on imports. In January 2024, Indian Immunologicals Ltd launched Havisure, India's first indigenously developed hepatitis A vaccine, significantly improving accessibility and affordability. Such regional innovations are expected to create substantial market opportunities through 2032.
Market Challenges
Cold-Chain Inefficiencies
Hepatitis A vaccines must be stored between 2°C and 8°C. Many lower-income regions lack adequate cold-chain infrastructure, resulting in vaccine wastage and reduced immunization coverage. These limitations remain a key barrier to market expansion.
Market Trends
Rising Demand for Traveler Immunization
With global travel increasing, the demand for hepatitis A vaccination among travelers has grown significantly. Travel clinics and pharmacies in high-income countries report strong vaccine uptake as travelers visit hepatitis A-endemic nations. South Korea, for example, strongly recommends at least one dose before travel to at-risk regions.
Segmentation Overview
By Type
The inactivated vaccine segment dominated the market in 2024 due to global approvals and wide availability. In 2023, SINOVAC's inactivated vaccine Healive gained regulatory approval in Kyrgyzstan. Live attenuated vaccines, though effective, remain regionally concentrated in India and China.
By Age Group
The pediatric segment led the market due to established vaccination protocols. The U.S. CDC recommends routine vaccination for all children aged 12-23 months.
By Form
Solution-based vaccines such as Vaqta (Merck) and Havrix (GSK) hold the majority share due to ease of administration. Lyophilized powders remain important for extended shelf life and storage benefits.
By Distribution Channel
Government suppliers dominated in 2024, driven by large-scale procurement programs. In 2025, GAVI allocated USD 250 million to enhance vaccine access in low-income countries.
Regional Outlook
North America - USD 0.62 Billion in 2024
North America led the global market, supported by high vaccination rates and rising disease incidence. The U.S. alone recorded 44,660 outbreak cases between 2016 and 2020, fueling vaccine demand.
Asia Pacific
Second-largest market with the highest projected CAGR. India, for instance, reported over 6,000 cases in the first half of 2024, prompting rapid vaccine adoption.
Europe
Strong government immunization programs and recent vaccine initiatives contribute to steady growth.
Latin America & Middle East/Africa
Despite lower market shares, rising awareness and targeted health campaigns support gradual adoption.
Conclusion
With the market valued at USD 1.24 billion in 2024, expected to reach USD 1.26 billion in 2025, and projected to attain USD 2.57 billion by 2032, the global hepatitis A vaccines market is positioned for substantial long-term expansion. Increasing disease burden, rising vaccination initiatives, and new indigenous vaccine developments will collectively drive growth throughout the forecast period.
Segmentation By Type
- Inactivated
- Live Attenuated
- Others
By Age Group
- Pediatric
- Adults
By Form
- Solution
- Lyophilized Powder
By Distribution Channel
- Hospital & Retail Pharmacies
- Government Suppliers
- Others
By Region
- North America (By Type, Age Group, Dose, Distribution Channel, and Country)
- U.S.
- Canada
- Europe (By Type, Age Group, Dose, Distribution Channel, and Country/Sub-region)
- U.K.
- Germany
- France
- Italy
- Spain
- Scandinavia
- Rest of Europe
- Asia Pacific (By Type, Age Group, Dose, Distribution Channel, and Country/Sub-region)
- Japan
- China
- India
- Australia
- Southeast Asia
- Rest of Asia Pacific
- Latin America (By Type, Age Group, Dose, Distribution Channel, and Country/Sub-region)
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa (By Type, Age Group, Dose, Distribution Channel, and Country/Sub-region)
- GCC
- South Africa
- Rest of the Middle East & Africa
Table of Content
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
4. Key Insights
- 4.1. Prevalence of Hepatitis A - by Key Countries/Regions, 2024
- 4.2. Pipeline Analysis, by Key Players
- 4.3. Technological Advancements in Market
- 4.4. New Product Launches, by Key Players
- 4.5. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
5. Global Hepatitis A Vaccines Market Analysis, Insights and Forecast, 2019-2032
- 5.1. Market Analysis, Insights and Forecast - By Type
- 5.1.1. Inactivated
- 5.1.2. Live Attenuated
- 5.1.3. Others
- 5.2. Market Analysis, Insights and Forecast - By Age Group
- 5.2.1. Pediatric
- 5.2.2. Adolts
- 5.3. Market Analysis, Insights and Forecast - By Form
- 5.3.1. Solution
- 5.3.2. Lyophilized Powder
- 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 5.4.1. Hospital & Retail Pharmacies
- 5.4.2. Government Suppliers
- 5.4.3. Others
- 5.5. Market Analysis, Insights and Forecast - Region
- 5.5.1. North America
- 5.5.2. Europe
- 5.5.3. Asia Pacific
- 5.5.4. Latin America
- 5.5.5. Middle East & Africa
6. North America Hepatitis A Vaccines Market Analysis, Insights and Forecast, 2019-2032
- 6.1. Market Analysis, Insights and Forecast - By Type
- 6.1.1. Inactivated
- 6.1.2. Live Attenuated
- 6.1.3. Others
- 6.2. Market Analysis, Insights and Forecast - By Age Group
- 6.2.1. Pediatric
- 6.2.2. Adolts
- 6.3. Market Analysis, Insights and Forecast - By Form
- 6.3.1. Solution
- 6.3.2. Lyophilized Powder
- 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 6.4.1. Hospital & Retail Pharmacies
- 6.4.2. Government Suppliers
- 6.4.3. Others
- 6.5. Market Analysis, Insights and Forecast - By Country
- 6.5.1. S.
- 6.5.2. Canada
7. Europe Hepatitis A Vaccines Market Analysis, Insights and Forecast, 2019-2032
- 7.1. Market Analysis, Insights and Forecast - By Type
- 7.1.1. Inactivated
- 7.1.2. Live Attenuated
- 7.1.3. Others
- 7.2. Market Analysis, Insights and Forecast - By Age Group
- 7.2.1. Pediatric
- 7.2.2. Adolts
- 7.3. Market Analysis, Insights and Forecast - By Form
- 7.3.1. Solution
- 7.3.2. Lyophilized Powder
- 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 7.4.1. Hospital & Retail Pharmacies
- 7.4.2. Government Suppliers
- 7.4.3. Others
- 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 7.5.1. Germany
- 7.5.2. K.
- 7.5.3. France
- 7.5.4. Italy
- 7.5.5. Spain
- 7.5.6. Scandinavia
- 7.5.7. Rest of Europe
8. Asia Pacific Hepatitis A Vaccines Market Analysis, Insights and Forecast, 2019-2032
- 8.1. Market Analysis, Insights and Forecast - By Type
- 8.1.1. Inactivated
- 8.1.2. Live Attenuated
- 8.1.3. Others
- 8.2. Market Analysis, Insights and Forecast - By Age Group
- 8.2.1. Pediatric
- 8.2.2. Adolts
- 8.3. Market Analysis, Insights and Forecast - By Form
- 8.3.1. Solution
- 8.3.2. Lyophilized Powder
- 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 8.4.1. Hospital & Retail Pharmacies
- 8.4.2. Government Suppliers
- 8.4.3. Others
- 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 8.5.1. China
- 8.5.2. Japan
- 8.5.3. India
- 8.5.4. Australia
- 8.5.5. Southeast Asia
- 8.5.6. Rest of Asia Pacific
9. Latin America Hepatitis A Vaccines Market Analysis, Insights and Forecast, 2019-2032
- 9.1. Market Analysis, Insights and Forecast - By Type
- 9.1.1. Inactivated
- 9.1.2. Live Attenuated
- 9.1.3. Others
- 9.2. Market Analysis, Insights and Forecast - By Age Group
- 9.2.1. Pediatric
- 9.2.2. Adolts
- 9.3. Market Analysis, Insights and Forecast - By Form
- 9.3.1. Solution
- 9.3.2. Lyophilized Powder
- 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 9.4.1. Hospital & Retail Pharmacies
- 9.4.2. Government Suppliers
- 9.4.3. Others
- 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 9.5.1. Brazil
- 9.5.2. Mexico
- 9.5.3. Rest of Latin America
10. Middle East & Africa Hepatitis A Vaccines Market Analysis, Insights and Forecast, 2019-2032
- 10.1. Market Analysis, Insights and Forecast - By Type
- 10.1.1. Inactivated
- 10.1.2. Live Attenuated
- 10.1.3. Others
- 10.2. Market Analysis, Insights and Forecast - By Age Group
- 10.2.1. Pediatric
- 10.2.2. Adolts
- 10.3. Market Analysis, Insights and Forecast - By Form
- 10.3.1. Solution
- 10.3.2. Lyophilized Powder
- 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 10.4.1. Hospital & Retail Pharmacies
- 10.4.2. Government Suppliers
- 10.4.3. Others
- 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 10.5.1. GCC
- 10.5.2. South Africa
- 10.5.3. Rest of Middle East & Africa
11. Competitive Analysis
- 11.1. Global Market Share Analysis (2024)
- 11.2. Company Profiles
- 11.2.1. GSK plc
- 11.2.1.1. Overview
- 11.2.1.2. Products & services
- 11.2.1.3. SWOT Analysis
- 11.2.1.4. Recent Developments
- 11.2.1.5. Strategies
- 11.2.1.6. Financials (Based on Availability)
- 11.2.2. Sanofi
- 11.2.2.1. Overview
- 11.2.2.2. Products & services
- 11.2.2.3. SWOT Analysis
- 11.2.2.4. Recent Developments
- 11.2.2.5. Strategies
- 11.2.2.6. Financials (Based on Availability)
- 11.2.3. Merck & Co., Inc.
- 11.2.3.1. Overview
- 11.2.3.2. Products & services
- 11.2.3.3. SWOT Analysis
- 11.2.3.4. Recent Developments
- 11.2.3.5. Strategies
- 11.2.3.6. Financials (Based on Availability)
- 11.2.4. Wockhardt
- 11.2.4.1. Overview
- 11.2.4.2. Products & services
- 11.2.4.3. SWOT Analysis
- 11.2.4.4. Recent Developments
- 11.2.4.5. Strategies
- 11.2.4.6. Financials (Based on Availability)
- 11.2.5. Indian Immunologicals Ltd (IIL)
- 11.2.5.1. Overview
- 11.2.5.2. Products & services
- 11.2.5.3. SWOT Analysis
- 11.2.5.4. Recent Developments
- 11.2.5.5. Strategies
- 11.2.5.6. Financials (Based on Availability)
- 11.2.6. SINOVAC
- 11.2.6.1. Overview
- 11.2.6.1.1. Products & services
- 11.2.6.1.2. SWOT Analysis
- 11.2.6.1.3. Recent Developments
- 11.2.6.1.4. Strategies
- 11.2.6.1.5. Financials (Based on Availability)
- 11.2.6.1. Overview
- 11.2.7. Vaxines Trading, Inc.
- 11.2.7.1. Overview
- 11.2.7.2. Products & services
- 11.2.7.3. SWOT Analysis
- 11.2.7.4. Recent Developments
- 11.2.7.5. Strategies
- 11.2.7.6. Financials (Based on Availability)
- 11.2.8. Boryung Biopharma Co.
- 11.2.8.1. Overview
- 11.2.8.2. Products & services
- 11.2.8.3. SWOT Analysis
- 11.2.8.4. Recent Developments
- 11.2.8.5. Strategies
- 11.2.8.6. Financials (Based on Availability)
- 11.2.1. GSK plc
List of Tables
- Table 1: Global Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Type, 2019-2032
- Table 2: Global Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2019-2033
- Table 3: Global Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Form, 2019-2034
- Table 4: Global Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
- Table 5: Global Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Region, 2019-2032
- Table 6: North America Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Type, 2019-2032
- Table 7: North America Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
- Table 8: North America Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Form, 2019-2032
- Table 9: North America Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
- Table 10: North America Hepatitis A Vaccines Market Revenue (USD billion) Forecast, By Country, 2019-2032
- Table 11: Europe Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Type, 2019-2032
- Table 12: Europe Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
- Table 13: Europe Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Form, 2019-2032
- Table 14: Europe Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
- Table 15: Europe Hepatitis A Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
- Table 16: Asia Pacific Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Type, 2019-2032
- Table 17: Asia Pacific Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
- Table 18: Asia Pacific Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Form, 2019-2032
- Table 19: Asia Pacific Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
- Table 20: Asia Pacific Hepatitis A Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
- Table 21: Latin America Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Type, 2019-2032
- Table 22: Latin America Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
- Table 23: Latin America Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Form, 2019-2032
- Table 24: Latin America Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
- Table 25: Latin America Hepatitis A Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
- Table 26: Middle East & Africa Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Type, 2019-2032
- Table 27: Middle East & Africa Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
- Table 28: Middle East & Africa Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Form, 2019-2032
- Table 29: Middle East & Africa Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
- Table 30: Middle East & Africa Hepatitis A Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
List of Figures
- Figure 1: Figure 1: Global Hepatitis A Vaccines Market Revenue Breakdown (USD billion, %) by Region, 2024 & 2032
- Figure 2: Global Hepatitis A Vaccines Market Value Share (%), by Type, 2024 & 2032
- Figure 3: Global Hepatitis A Vaccines Market Value Share (%), by Age Group, 2024 & 2032
- Figure 4: Global Hepatitis A Vaccines Market Value Share (%), by Form 2024 & 2032
- Figure 5: Global Hepatitis A Vaccines Market Value Share (%), by Distribution Channel, 2024 & 2032
- Figure 6: Global Hepatitis A Vaccines Market Value Share (%), by Region, 2024 & 2032
- Figure 7: North America Hepatitis A Vaccines Market Value (USD billion), by Type, 2024 & 2032
- Figure 8: North America Hepatitis A Vaccines Market Value Share (%), by Type, 2024
- Figure 9: North America Hepatitis A Vaccines Market Value (USD billion), by Age Group, 2024 & 2032
- Figure 10: North America Hepatitis A Vaccines Market Value Share (%), by Age Group, 2024
- Figure 11: North America Hepatitis A Vaccines Market Value (USD billion), by Form, 2024 & 2032
- Figure 12: North America Hepatitis A Vaccines Market Value Share (%), by Form, 2024
- Figure 13: North America Hepatitis A Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
- Figure 14: North America Hepatitis A Vaccines Market Value Share (%), by Distribution Channel, 2024
- Figure 15: North America Hepatitis A Vaccines Market Value (USD billion), By Country, 2024 & 2032
- Figure 16: North America Hepatitis A Vaccines Market Value Share (%), By Country, 2024
- Figure 17: Europe Hepatitis A Vaccines Market Value (USD billion), by Type, 2024 & 2032
- Figure 18: Europe Hepatitis A Vaccines Market Value Share (%), by Type, 2024
- Figure 19: Europe Hepatitis A Vaccines Market Value (USD billion), by Age Group, 2024 & 2032
- Figure 20: Europe Hepatitis A Vaccines Market Value Share (%), by Age Group, 2024
- Figure 21: Europe Hepatitis A Vaccines Market Value (USD billion), by Form, 2024 & 2032
- Figure 22: Europe Hepatitis A Vaccines Market Value Share (%), by Form, 2024
- Figure 23: Europe Hepatitis A Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
- Figure 24: Europe Hepatitis A Vaccines Market Value Share (%), by Distribution Channel, 2024
- Figure 25: Europe Hepatitis A Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
- Figure 26: Europe Hepatitis A Vaccines Market Value Share (%), By Country/ Sub-region, 2024
- Figure 27: Asia Pacific Hepatitis A Vaccines Market Value (USD billion), by Type, 2024 & 2032
- Figure 28: Asia Pacific Hepatitis A Vaccines Market Value Share (%), by Type, 2024
- Figure 29: Asia Pacific Hepatitis A Vaccines Market Value (USD billion), by Age Group, 2024 & 2032
- Figure 30: Asia Pacific Hepatitis A Vaccines Market Value Share (%), by Age Group, 2024
- Figure 31: Asia Pacific Hepatitis A Vaccines Market Value (USD billion), by Form, 2024 & 2032
- Figure 32: Asia Pacific Hepatitis A Vaccines Market Value Share (%), by Form, 2024
- Figure 33: Asia Pacific Hepatitis A Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
- Figure 34: Asia Pacific Hepatitis A Vaccines Market Value Share (%), by Distribution Channel, 2024
- Figure 35: Asia Pacific Hepatitis A Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
- Figure 36: Asia Pacific Hepatitis A Vaccines Market Value Share (%), By Country/ Sub-region, 2024
- Figure 37: Latin America Hepatitis A Vaccines Market Value (USD billion), by Type, 2024 & 2032
- Figure 38: Latin America Hepatitis A Vaccines Market Value Share (%), by Type, 2024
- Figure 39: Latin America Hepatitis A Vaccines Market Value (USD billion), by Age Group, 2024 & 2032
- Figure 40: Latin America Hepatitis A Vaccines Market Value Share (%), by Age Group, 2024
- Figure 41: Latin America Hepatitis A Vaccines Market Value (USD billion), by Form, 2024 & 2032
- Figure 42: Latin America Hepatitis A Vaccines Market Value Share (%), by Form, 2024
- Figure 43: Latin America Hepatitis A Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
- Figure 44: Latin America Hepatitis A Vaccines Market Value Share (%), by Distribution Channel, 2024
- Figure 45: Latin America Hepatitis A Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
- Figure 46: Latin America Hepatitis A Vaccines Market Value Share (%), By Country/ Sub-region, 2024
- Figure 47: Middle East & Africa Hepatitis A Vaccines Market Value (USD billion), by Type, 2024 & 2032
- Figure 48: Middle East & Africa Hepatitis A Vaccines Market Value Share (%), by Type, 2024
- Figure 49: Middle East & Africa Hepatitis A Vaccines Market Value (USD billion), by Age Group, 2024 & 2032
- Figure 50: Middle East & Africa Hepatitis A Vaccines Market Value Share (%), by Age Group, 2024
- Figure 51: Middle East & Africa Hepatitis A Vaccines Market Value (USD billion), by Form, 2024 & 2032
- Figure 52: Middle East & Africa Hepatitis A Vaccines Market Value Share (%), by Form, 2024
- Figure 53: Middle East & Africa Hepatitis A Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
- Figure 54: Middle East & Africa Hepatitis A Vaccines Market Value Share (%), by Distribution Channel, 2024
- Figure 55: Middle East & Africa Hepatitis A Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
- Figure 56: Middle East & Africa Hepatitis A Vaccines Market Value Share (%), By Country/ Sub-region, 2024
- Figure 57: Global Hepatitis A Vaccines Market Share (%), By Company, 2024
